Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signalingR. P. Tripathi, Rina Plattner, Christina Meeks et al.|Nature Communications|2020Cited by 51
ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF HomodimerizationAnastasia Lyon, Rina Plattner, R. P. Tripathi et al.|Cancers|2023Cited by 3